Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Zyprexa (correction)

Executive Summary

Lilly received an "approvable" letter from FDA on April 30 for its submission of two sNDAs for Zyprexa (olanzapine) for the treatment of schizophrenia and acute mixed or manic episodes associated with bipolar I disorder in adolescents, ages 13 to 17. A recent article in "The Pink Sheet" misstates the ages for proposed pediatric indications (1"The Pink Sheet" June 25, 2007, In Brief)...

You may also be interested in...

Risperdal, Zyprexa “approvable’ for teen schizophrenia

FDA issues an "approvable" letter June 21 to Johnson & Johnson unit Janssen for Risperdal (risperidone) to treat schizophrenia in children ages 13-17. A potential competitor in the space, Lilly's Zyprexa (olanzapine), is also approvable for an identical indication. Lilly told "The Pink Sheet" it received an approvable letter April 30 for Zyprexa to treat teen schizophrenia and acute mania associated with bipolar I disorder in children ages 10-17 years. FDA did not request any new clinical trials for either drug, according to the firms. The sNDAs for both drugs received "priority" review...

'Touchless Plants' To Virtually Trained Workforces - Indian Cos Share Digitalization Tips

Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.

More IVD Mergers: Agilent Buys Resolution, Hologic Acquires Diagenode

Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts